From Early Clinical Promise to Make‑or‑Break Moments
Until a few years ago, TCR therapies represented an interesting but unproven alternative to CAR‑T. In 2026, the tone has shifted.
The field now spans engineered TCR‑T-cells, TCR mimicking antibodies, and TCR bispecifics, all converging on the goal of reaching intracellular targets. Clinical programs are advancing across solid tumors with growing momentum and expanding both into haem malignancies and beyond oncology, into autoimmunity and even infectious diseases.
While momentum is undeniable, the industry is acutely aware that scientific wins alone are not enough. With cost of goods rising, treatable patient populations shrinking due to HLA restrictions, and durability remaining inconsistent, developers face the reality that TCR innovation must now deliver conceptually, clinically, and commercially.
Advancing the Next Wave of TCR Engineering Innovation
This shift in charge has been driven by broad, cross-modality innovation. Key players including Immatics, Immunocore, Regeneron, Anocca, ZellunaImmunotherapy and BioNTech are exploring new target discovery, dual activation engineering, and AI/machine learning-assisted affinity maturation. Together, these advances are enabling developers to engineer TCRs faster and more precisely, reducing uncertainty and process inefficiency as programs move toward the clinic.
Rewriting the Rules on Target Selection
We have also seen target innovation gather pace, as developers move beyond PRAME and other familiar antigens, towards a broader set of target classes, including non-canonical antigens. The goal is to widen the pool of eligible patients, counter tumor escape, and drive response rates in indications where conventional TCR programs have their drawbacks.
Facing the Commercial Barriers That Determine Long-Term Viability
Despite this, the past year has shown that regulatory green lights do not guarantee long term commercial success. Manufacturing strategy, scalability and cost of goods now shape viability just as much as clinical outcomes. The field is no longer debating scientific potential but confronting what is required to turn innovation into a sustainable pipeline of TCR-based therapies.
Creating the Space the TCR Field Needs to Move Forward
The TCR field is small, specialized and deeply interconnected, which makes genuine expert convergence more valuable than ever. This year’s summit brings together industry leaders for focused conversations that rarely happen in isolation and are impossible to hold in rooms diluted by thousands of attendees or during broader agendas.
By uniting cell and biologic-based TCR developers, the meeting creates an environment where discovery, translational, manufacturing and clinical teams can examine durability, specificity, target selection and commercial viability as parts of a single, interconnected challenge.
2026 represents a turning point for the field, and the community needs a space dedicated to translating scientific promise into therapies that are durable, scalable, and commercially sustainable.